Pharmaxis Ltd (AU:SNT) has released an update. Syntara Limited’s interim results from its Phase 2 trial for the myelofibrosis treatment ...

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

The Company's partner, Incyte, is now recruiting patients for a Phase 2, open-label, randomized, multicenter trial of axatilimab in combination with ruxolitinib in patients ≥12 years of age with newly ...

The full abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical ...

0:09 | The 4 approved drugs have different [adverse] effects. Ruxolitinib [Jakafi] is most known for the cytopenias that it causes, and same with fedratinib [Inrebic]. For both of them, anemia, ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK Inhibitors). It is an inhibitor of the JAK1 and ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat.com reports. One ...